• 1
    Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010; 31: 55766.
  • 2
    Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 2008; 6: 34466.
  • 3
    Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009; 124: 195206.
  • 4
    Chien CC, Pasternak GW. Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid system. Eur J Pharmacol 1993; 250: R7R8.
  • 5
    Chien CC, Pasternak GW. Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther 1994; 271: 158390.
  • 6
    Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett 1995; 190: 1379.
  • 7
    Mei J, Pasternak GW. Sigma 1 receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther 2002; 300: 10704.
  • 8
    Kim FJ, Kovalyshyn I, Burgman M, Neilan C, Chien CC, Pasternak GW. Sigma-1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol Pharmacol 2010; 77: 695710.
  • 9
    De la Puente B, Nadal X, Portillo-Salido E, Sánchez-Arroyos R, Ovalle S, Palacios G, Muro A, Romero L, Entrena JM, Baeyens JM, López-García JA, Maldonado R, Zamanillo D, Vela JM. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain 2009; 145: 294303.
  • 10
    Entrena JM, Cobos EJ, Nieto FR, Cendán CM, Gris G, Del Pozo E, Zamanillo D, Baeyens JM. Sigma-1 receptors are essential for capsaicin-induced mechanical hypersensitivity: studies with selective sigma-1 ligands and sigma-1 knockout mice. Pain 2009; 143: 25261.
  • 11
    Entrena JM, Cobos EJ, Nieto FR, Cendán CM, Baeyens JM, Del Pozo E. Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. Psychopharmacology 2009; 205: 2133.
  • 12
    Rho DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na HS, Lee JH. Intrathecal injection of the sigma-1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology 2008; 109: 87989.
  • 13
    Díaz JL, Zamanillo D, Corbera J, Baeyens JM, Maldonado R, Pericàs MA, Vela JM, Torrens A. Selective sigma-1 (sigma1) receptor antagonists: emerging target for the treatment of neuropathic pain. Cent Nerv Syst Agents. Med Chem 2009; 9: 17283.
  • 14
    Romero L, Zamanillo D, Nadal X, Sánchez-Arroyos R, Rivera-Arconada I, Dordal A, Montero A, Muro A, Bura A, Segalés C, Laloya M, Hernández E, Portillo-Salido E, Escriche M, Codony X, Encina G, Burgueño J, Merlos M, Baeyens J, Giraldo J, López-García JA, Maldonado R, Plata-Salamán CR, Vela JM. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol 2012; Accepted Article, doi: 10.1111/j.1476-5381.2012.01942.x.
  • 15
    Vidal A, Touriño C, Romero L, Baeyens JM, Zamanillo D, Maldonado R, Vela JM. Potentiation of morphine analgesia but inhibition of the rewarding effect of morphine following co-administration of a new selective sigma-1 receptor antagonist (S1RA). Eur J Pain 2009; 13: (Suppl. 1): S104.
  • 16
    Arasteh K, Poudevida S, Farre M, Roset PN, Cami J. Response patterns of the Spanish version of the 49-item short form of the Addiction Research Center Inventory after the use of sedatives, stimulants, and opioids. Drug Alcohol Depend 1999; 55: 11725.
  • 17
    Saletu B, Wessely P, Grünberger J, Schultes M. Erste klinische Erfahrungen mit einem neuen schlafanstoßenden Benzodiazepin, Cinolazepam, mittels eines Selbstbeurteilungsbogens für Schlaf- und Aufwachqualität (SSA). Neuropsychiatrie 1987; 1: 16976.
  • 18
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Center for Veterinary Medicine 2001; Guidance for industry: bioanalytical method validation. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Washington D.C. Available at: (last accessed 30 January 2012).
  • 19
    Smith B, Vandenhende F, DeSante K, Farid NA, Welch PA, Callaghan JT, Forgue ST. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000; 17: 127883.
  • 20
    Smith B. Assessment of dose proportionality. In: Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, eds Bonate P, Howard D. Arlington, VA: AAPS Press, 2004; 36382.
  • 21
    Patterson ST, Smith B. Analysis of human pharmacokinetic data. In: Pharmaceutical Statistics Using SAS – A Practical Guide, eds Dmitrienko A, Chuang-Stein C, D'Agostino R. Cary NC: SAS Press, 2008; 197211.